
Kwality Pharmaceuticals has announced its consolidated audited results for the quarter and year ending March 31, 2026.
The company has shown significant growth in both revenue and profit, reflecting its robust performance in the pharmaceutical sector.
For the quarter ending March 31, 2026, Kwality Pharmaceuticals reported a total revenue of ₹158.17 crore, marking a 35.8% increase compared to ₹116.44 crore in the same quarter of the previous year.
Sequentially, revenue rose by 27.6% from ₹123.97 crore in the December 2025 quarter.
Net profit for the March 2026 quarter surged by 74.8% year-on-year to ₹25.31 crore, up from ₹14.48 crore in the corresponding quarter last year.
Compared to the December 2025 quarter, net profit increased by 58.2% from ₹16.00 crore.
For the financial year ending March 31, 2026, Kwality Pharmaceuticals achieved a total revenue of ₹505.94 crore, representing a 36% year-on-year growth from ₹372.12 crore in FY25.
The company's net profit for FY26 rose by 69.2% to ₹67.35 crore, compared to ₹39.80 crore in the previous financial year.
Read More: Zydus Lifesciences Share Price Gains Over 5% After Q4 FY26 Earnings Results: Net Profit up 8.7% YoY!
The substantial increase in both quarterly and annual revenue and profit figures highlights Kwality Pharmaceuticals' strong market position and effective business strategies.
The company's ability to achieve significant growth in a competitive market underscores its operational efficiency and strategic planning.
As of May 20, 2026, at 11:52 AM, Kwality Pharmaceuticals share price on NSE was trading at ₹2,141.90 up by 7.06% from the previous closing price.
Kwality Pharmaceuticals has demonstrated impressive financial growth in Q4 and FY26, with notable increases in both revenue and net profit. The company's performance reflects its strong market presence and successful execution of business strategies.
Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 20, 2026, 12:11 PM IST

Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
